Production (Stage)
Avalo Therapeutics, Inc.
AVTX
$3.75
-$0.16-4.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 192.00K | 249.00K | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 192.00K | 249.00K | 0.00 | -- |
| Cost of Revenue | 5.91M | 5.54M | 6.50M | 2.86M | 388.00K |
| Gross Profit | -5.91M | -5.35M | -6.25M | -2.86M | -388.00K |
| SG&A Expenses | 5.55M | 5.23M | 4.29M | 4.53M | 3.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.67M | 13.50M | 13.11M | 9.47M | 5.23M |
| Operating Income | -14.67M | -13.31M | -12.86M | -9.47M | -5.23M |
| Income Before Tax | -13.14M | -35.23M | 23.02M | 98.47M | -121.28M |
| Income Tax Expenses | 8.00K | 114.00K | -14.00K | 7.00K | 7.00K |
| Earnings from Continuing Operations | -13.15M | -35.34M | 23.04M | 98.46M | -121.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.15M | -35.34M | 23.04M | 98.46M | -121.29M |
| EBIT | -14.67M | -13.31M | -12.86M | -9.47M | -5.23M |
| EBITDA | -14.53M | -13.24M | -12.83M | -9.44M | -5.20M |
| EPS Basic | -1.25 | -3.44 | 0.98 | 0.93 | -141.14 |
| Normalized Basic EPS | -0.78 | -2.15 | 2.59 | 2.63 | -68.18 |
| EPS Diluted | -1.25 | -3.44 | -2.83 | -3.86 | -141.14 |
| Normalized Diluted EPS | -0.78 | -2.15 | 1.33 | 2.63 | -68.18 |
| Average Basic Shares Outstanding | 10.51M | 10.23M | 5.55M | 23.39M | 859.40K |
| Average Diluted Shares Outstanding | 10.51M | 10.23M | 10.78M | 23.39M | 859.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |